Pharmacokinetics, Mass Balance, and Biotransformation of [14C]tinengotinib, A Novel Multi-target Kinase Inhibitor, in Healthy Subjects - Ni, Shumao; Ma, Sheng; Yu, Yingying; Yu, Zhenwen; Zhu, Yujia; Sun, Xiaofen; Li, Lin; Sun, Caixia; Wang, Hui; Peng, Peng; Gu, Zheming; Zhang, Hua; et al. (Drugs in R&D, 2024)
Keywords: Administration, Oral; Adult; Biotransformation; Breast cancer; Carbon Radioisotopes; Clinical trials; CTR; CTR20212852; Drug dosages; Drug interactions; Enzymes; Feces; Feces - chemistry; Growth factors; Half-Life; Healthy Volunteers; Humans; Internal Medicine; Kinases; Male; Medical prognosis; Medicine; Medicine & Public Health; Metabolism; Metabolites; Molecules; Original; Original Research Article; Pharmacokinetics; Pharmacology/Toxicology; Pharmacotherapy; Plasma; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - pharmacokinetics; Protein Kinase Inhibitors - urine; Pyridines; Triazoles; Urine; Young Adult; United Kingdom--UK; United States--US; China